# Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence

> **NCT05806164** · PHASE4 · RECRUITING · sponsor: **Women and Infants Hospital of Rhode Island** · enrollment: 432 (estimated)

## Conditions studied

- Urgency Urinary Incontinence

## Interventions

- **DRUG:** Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]
- **DRUG:** OnabotulinumtoxinA 100 UNT [Botox]

## Key facts

- **NCT ID:** NCT05806164
- **Lead sponsor:** Women and Infants Hospital of Rhode Island
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-06
- **Primary completion:** 2026-07-15
- **Final completion:** 2030-08-01
- **Target enrollment:** 432 (ESTIMATED)
- **Last updated:** 2025-09-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05806164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05806164, "Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05806164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*